- Home
- KROS vs EYPT Comparison
KROS vs EYPT Comparison
Compare KROS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- EYPT
- Stock Information
- Founded
- KROS 2015
- EYPT 1987
- Country
- KROS United States
- EYPT United States
- Employees
- KROS N/A
- EYPT N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- KROS Health Care
- EYPT Industrials
- Exchange
- KROS Nasdaq
- EYPT Nasdaq
- Market Cap
- KROS 558.9M
- EYPT 579.4M
- IPO Year
- KROS 2020
- EYPT 2005
- Fundamental
- Price
- KROS $13.45
- EYPT $9.72
- Analyst Decision
- KROS Buy
- EYPT Strong Buy
- Analyst Count
- KROS 13
- EYPT 8
- Target Price
- KROS $20.63
- EYPT $24.75
- AVG Volume (30 Days)
- KROS 603.2K
- EYPT 800.0K
- Earning Date
- KROS 08-06-2025
- EYPT 08-06-2025
- Dividend Yield
- KROS N/A
- EYPT N/A
- EPS Growth
- KROS N/A
- EYPT N/A
- EPS
- KROS 0.11
- EYPT N/A
- Revenue
- KROS $214,713,000.00
- EYPT $56,042,000.00
- Revenue This Year
- KROS $5,006.76
- EYPT N/A
- Revenue Next Year
- KROS N/A
- EYPT N/A
- P/E Ratio
- KROS $123.44
- EYPT N/A
- Revenue Growth
- KROS 91657.70
- EYPT 12.04
- 52 Week Low
- KROS $9.12
- EYPT $3.91
- 52 Week High
- KROS $72.37
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- KROS 45.45
- EYPT 62.47
- Support Level
- KROS $13.24
- EYPT $8.96
- Resistance Level
- KROS $13.77
- EYPT $10.20
- Average True Range (ATR)
- KROS 0.37
- EYPT 0.76
- MACD
- KROS -0.04
- EYPT -0.03
- Stochastic Oscillator
- KROS 38.67
- EYPT 62.90
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.